SCHEMBL5651827

SCHEMBL5651827

CN(C(=O)Oc1ccc(Cc2cccnc2)cc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 4/20 0.54
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TBXAS1 P24557 8/20 0.50
LTA4H P09960 1/20 0.49
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GRM2 Q14416 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649619 0.88 RAB9A (0.66) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5649849 0.83 LIPE (0.52) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5650878 0.83 RAB9A (0.54) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5649597 0.82 RAB9A (0.61) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL3764742 0.82 LIPE (0.56) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5648895 0.82 LIPE (0.56) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5647911 0.81 LIPE (0.50) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5650031 0.81 LIPE (0.57) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5651693 0.79 RAB9A (0.54) LIPERAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5681478 0.79 RAB9A (0.51) LIPERAB9ASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148860-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US claimed
EP-1636188-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111006-A1 PARA-SUBTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-20060148860-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1636188-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111006-A1 PARA-SUBTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148860-A1 Substituted p-phenyl carbamates LIPE, PNLIP, LPL LIPE 1/4885RAB9A 1647/4885SMN1; SMN2 2599/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL LIPE 1/4885RAB9A 2926/4885SMN1; SMN2 4233/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL LIPE 1/4885RAB9A 3386/4885SMN1; SMN2 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.